Solid Biosciences (SLDB) Q4 2024 earnings summary

Executive summary

• Reported positive initial data from the INSPIRE DUCHENNE trial for SGT-003, showing promising safety and biomarker improvements in Duchenne muscular dystrophy patients.

• FDA cleared IND for SGT-212, the first gene therapy using a dual route for Friedreich's ataxia; first participant dosing expected in 2H 2025.

• IND for SGT-501 (CPVT) on track for 1H 2025 submission; Mayo Clinic collaboration expands cardiac gene therapy pipeline.

• Ended 2024 with $148.9M in cash and equivalents; $200M equity offering in Feb 2025 extends cash runway into 1H 2027.

Financial highlights

• Cash, cash equivalents, and available-for-sale securities totaled $148.9M at year-end 2024, up from $123.6M at year-end 2023.

• R&D expenses rose to $96.4M for 2024 from $76.6M in 2023, mainly due to increased costs for SGT-501 and SGT-212.

• G&A expenses increased to $33.3M in 2024 from $27.8M in 2023, primarily from higher personnel costs.

• Net loss for 2024 was $124.7M, compared to $96.0M in 2023; Q4 2024 net loss was $42.6M versus $20.3M in Q4 2023.

Outlook and guidance

• Plans to request FDA meeting in mid-2025 for potential accelerated approval of SGT-003.

• Expects to dose over 10 participants in SGT-003 trial by early Q2 2025 and about 20 by Q4 2025.

• SGT-212 Phase 1b trial for FA to begin in 2H 2025; SGT-501 IND submission anticipated in 1H 2025.

• Cash runway projected into 1H 2027 with recent equity raise.